News

• March 10, 2008
  

  US News & World Report – Genetic Tests Predict Response to Warfarin

  Variations of a gene that determines a person’s sensitivity to warfarin are important in determining the initial doses of the anti-clotting drug, researchers report.
• March 10, 2008
  

  Tucson Citizen – Blood Thinner Safety Effort Touted

  A Tucson-based research institute says it is improving the safety of a widely used blood thinning drug.
• February 10, 2008
  

  Alastair J.J. Wood Joins the Critical Path Institute Board of Directors

  Dr. Alastair J.J. Wood, drug development authority, frequent advisor to the Food and Drug Administration (FDA) and former Assistant Vice Chancellor for Research at Vanderbilt University was recently named to the Board of Directors of the Critical Path Institute.
• January 10, 2008
  

  Peter Corr Joins the Critical Path Institute Board of Directors

  The Critical Path Institute today announced that Peter B. Corr, Ph.D., has joined its Board of Directors. Dr. Corr has more than 30 years of pharmacology and pharmaceutical development experience as both an academician and a senior executive in the pharmaceutical industry.
• October 10, 2007
  

  C-Path and Ventana Medical Systems to Collaborate

  The Critical Path Institute (C-Path) and Ventana Medical Systems, Inc. (Ventana) (NASDAQ: VMSI) today released additional information about C-Path’s $2.1 million grant from Science Foundation Arizona (SFAz) to fund a collaboration project with the U.S. Food and Drug Administration (FDA) and the National Cancer Institute (NCI) to develop a standard testing and evaluation process for...